Screener
Arcus Biosciences RCUS CapEx
CapEx at other companies
Other financials
Where this comes from
Reported directly by Arcus Biosciences in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: Arcus Biosciences’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:11 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001724521-26-000044
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Purchases of marketable securities | (332) | (514) |
| Proceeds from maturities of marketable securities | 482 | 615 |
| Proceeds from sales of marketable securities | 16 | 69 |
| Purchases of property and equipment | — | (1) |
| Net cash provided by investing activities | 166 | 169 |
| Cash flows from financing activities | ||
| Proceeds from issuance of common stock ($— and $14 from a related party) | — | 142 |
| Proceeds from debt issuances, net | — | 49 |
Item 1. Financial Statements
FAQ
- What is Arcus Biosciences's capex?
- Arcus Biosciences (RCUS) reported capex of $0 in Q2 2026.
- What is the long-term trend for Arcus Biosciences's capex?
- Over 3 years (2021 to 2024), Arcus Biosciences's capex has grown at a -38.7% compound annual growth rate (CAGR), from $26M to $6M.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about Arcus Biosciences's capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude